A1M Pharma

Research findings deepen the knowledge of A1M’s ability to neutralize toxic free hemoglobin

Thu, Nov 12, 2015 09:14 CET

A scientific article published by scientists associated with A1M Pharma explains the process behind the protein A1M’s ability to neutralize free hemoglobin. The article has been approved for publishing in the scientific journal Biochim Biophys Acta (BBA) in January 2016 and is already available in their online version.A1M Pharma is developing treatment for pre-eclampsia and acute kidney injury, two indications where the damaging effects of free hemoglobin play a vital part. It is the so-called heme groups of the hemoglobin that can damage the cells in the body, and the article explains how

Two new Swedish PhD thesis support scientific rationale for the treatment of oxidative stress with A1M protein

Tue, Oct 20, 2015 08:41 CET

Two recently published PhD thesis from Lund University strengthen the scientific basis of the protein A1M's protective mechanism of action in connection with oxidative stress. Firstly, the potential of fetal hemoglobin and A1M as biomarkers of pre-eclampsia is verified in a larger patient group than previously and secondly A1M's therapeutic effects on oxidative stress is demonstrated for the first time in an animal model in the placenta and kidney and skin and eye cells.The first thesis, written by Ulrik Dolberg Anderson, under the supervision of A1M Pharma's co-founder, Professor Stefan

Share

Research findings deepen the knowledge of A1M’s ability to neutralize toxic free hemoglobin

Two new Swedish PhD thesis support scientific rationale for the treatment of oxidative stress with A1M protein